Aziyo biologics appoints dr. c. randal mills as interim president and ceo

Silver spring, md., june 21, 2022 (globe newswire) -- aziyo biologics, inc. (nasdaq: azyo), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced aziyo co-founder c. randal (randy) mills, ph.d., has been appointed interim president and ceo. ronald lloyd will step down from these positions but will remain with the company through the end of the third quarter to assist with the transition. aziyo co-founder kevin rakin has also assumed the role of executive chairman.
AZYO Ratings Summary
AZYO Quant Ranking